Evidence map›Paper›PMID 24574394›Full record

ArticleJournal of virology2014

In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Nadine Althof, Stephanie Harkins, Christopher C Kemball, Claudia T Flynn, Mehrdad Alirezaei, J Lindsay Whitton

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. METTL14-dependent mbioRxiv : the preprint server for biology · 2026
    Article
  3. Cardiomyocyte β-arrestins mediate inflammation and cGAS-STING activation in CVB3 viral myocarditis.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Interferons and interferon-related pathways in heart disease.Frontiers in cardiovascular medicine · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nadine AlthofDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Stephanie Harkins
Christopher C Kemball
Claudia T Flynn
Mehrdad Alirezaei
J Lindsay Whitton
Scripps Research Institute · US

Funding

COXSACKIE MYOCARDITIS AND VIRAL PERSISTENCE IN THE HEARTR01AI042314 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WHITTON, J. LINDSAY · 1998 to 2013
$5.6M
TRAINING IN IMMUNOLOGY AND MOLECULAR PATHOGENESIST32AI007610 · NIAID · EMORY UNIVERSITY · PI EVAVOLD, BRIAN D · 2000 to 2014
$4.4M
Analyzing the effects of type I interferons in the enterovirus-infected heartR01AI110621 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WHITTON, J. LINDSAY · 2015 to 2019
$3.4M
Innate and Adaptive Immune Responses in the Virus-Infected HeartR01HL093177 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI WHITTON, J. LINDSAY · 2010 to 2013
$1.9M
NHLBI NIH HHS HL093177NHLBI NIH HHS R01 HL093177NIAID NIH HHS AI042314NIAID NIH HHS R01 AI042314NIAID NIH HHS R01 AI110621NIAID NIH HHS T32 AI007610
6 · The paper itself

Abstract

unlabelledAcute coxsackievirus B3 (CVB3) infection is one of the most prevalent causes of acute myocarditis, a disease that frequently is identified only after the sudden death of apparently healthy individuals. CVB3 infects cardiomyocytes, but the infection is highly focal, even in the absence of a strong adaptive immune response, suggesting that virus spread within the heart may be tightly constrained by the innate immune system. Type I interferons (T1IFNs) are an obvious candidate, and T1IFN receptor (T1IFNR) knockout mice are highly susceptible to CVB3 infection, succumbing within a few days of challenge. Here, we investigated the role of T1IFNs in the heart using a mouse model in which the T1IFNR gene can be ablated in vivo, specifically in cardiomyocytes. We found that T1IFN signaling into cardiomyocytes contributed substantially to the suppression of viral replication and infectious virus yield in the heart; in the absence of such signaling, virus titers were markedly elevated by day 3 postinfection (p.i.) and remained high at day 12 p.i., a time point at which virus was absent from genetically intact littermates, suggesting that the T1IFN-unresponsive cardiomyocytes may act as a safe haven for the virus. Nevertheless, in these mice the myocardial infection remained highly focal, despite the cardiomyocytes' inability to respond to T1IFN, indicating that other factors, as yet unidentified, are sufficient to prevent the more widespread dissemination of the infection throughout the heart. The absence of T1IFN signaling into cardiomyocytes also was accompanied by a profound acceleration and exacerbation of myocarditis and by a significant increase in mortality. IMPORTANCE: Acute coxsackievirus B3 (CVB3) infection is one of the most common causes of acute myocarditis, a serious and sometimes fatal disease. To optimize treatment, it is vital that we identify the immune factors that limit virus spread in the heart and other organs. Type I interferons play a key role in controlling many virus infections, but it has been suggested that they may not directly impact CVB3 infection within the heart. Here, using a novel line of transgenic mice, we show that these cytokines signal directly into cardiomyocytes, limiting viral replication, myocarditis, and death.

Indexed as

AnimalsCoxsackievirus InfectionsDisease Models, AnimalEnterovirus B, HumanMiceMice, KnockoutMice, TransgenicMyocarditisMyocytes, CardiacReceptor, Interferon alpha-betaSurvival AnalysisReceptor, Interferon alpha-beta

Identifiers

PMID24574394
PMCPMC3993796
OpenAlexW2019947482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.